DUAL II China: superior HbA 1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

Diabetes Obesity and Metabolism ◽

10.1111/dom.14522 ◽

2021 ◽

Author(s):

Yu Pei ◽

Bue R. Agner ◽

Bin Luo ◽

Xiaolin Dong ◽

Dongmei Li ◽

...

Keyword(s):

Type 2 Diabetes ◽

Weight Loss ◽

Randomized Trial ◽

Basal Insulin ◽

Insulin Degludec ◽

Download Full-text

Short-term, temporary insulin degludec, an ultra-long-acting basal insulin, as compared with glargine on the glycemic control in Japanese patients with type 2 diabetes

Endocrine Abstracts ◽

10.1530/endoabs.32.p477 ◽

2013 ◽

Author(s):

Shizuka Kaneko ◽

Yumiko Tahara ◽

Yuichi Sato ◽

Masao Tashima

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Basal Insulin ◽

Japanese Patients ◽

Insulin Degludec ◽

Download Full-text

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal–bolus therapy in type 1 and type 2 diabetes

Annales d Endocrinologie ◽

10.1016/j.ando.2013.04.004 ◽

2013 ◽

Vol 74 (5-6) ◽

pp. 487-490 ◽

Author(s):

Véronique Kerlan ◽

Didier Gouet ◽

Michel Marre ◽

Éric Renard

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Insulin Degludec ◽

Duration Of Action ◽

Long Duration ◽

Download Full-text

Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12960 ◽

2017 ◽

Vol 19 (10) ◽

pp. 1490-1494 ◽

Author(s):

Muriel Metzger ◽

Javier Castañeda ◽

Yves Reznik ◽

Francesco Giorgino ◽

Ignacio Conget ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Randomized Trial ◽

Basal Insulin ◽

Continuous Subcutaneous Insulin Infusion ◽

Insulin Infusion ◽

Infusion Therapy ◽

Subcutaneous Insulin ◽

Factors Associated

Download Full-text

Patient characteristics and 6‐month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment ( ORBIT )

Journal of Diabetes ◽

10.1111/1753-0407.13046 ◽

2020 ◽

Vol 12 (9) ◽

pp. 668-676

Author(s):

Leili Gao ◽

Puhong Zhang ◽

Jianping Weng ◽

Juming Lu ◽

Xiaohui Guo ◽

...

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Insulin Treatment ◽

Patient Characteristics ◽

Download Full-text

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis

Diabetes Therapy ◽

10.1007/s13300-019-0624-4 ◽

2019 ◽

Vol 10 (3) ◽

pp. 835-852 ◽

Author(s):

Wenchuan Zhou ◽

Jinxin Tao ◽

Xiaodong Zhou ◽

Hongxia Chen

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Insulin Degludec ◽

Download Full-text

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

10.1016/s0140-6736(10)62305-7 ◽

2011 ◽

Vol 377 (9769) ◽

pp. 924-931 ◽

Author(s):

Bernard Zinman ◽

Greg Fulcher ◽

Paturi V Rao ◽

Nihal Thomas ◽

Lars A Endahl ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Download Full-text

One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes: A randomized trial

Diabetes Care ◽

10.2337/diacare.26.9.2505 ◽

2003 ◽

Vol 26 (9) ◽

pp. 2505-2511 ◽

Author(s):

J. B. Redmon ◽

S. K. Raatz ◽

K. P. Reck ◽

J. E. Swanson ◽

C. A. Kwong ◽

...

Keyword(s):

Type 2 Diabetes ◽

Weight Loss ◽

Randomized Trial ◽

Download Full-text

Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial

Journal of Bone and Mineral Research ◽

10.1002/jbmr.1483 ◽

2012 ◽

Vol 27 (3) ◽

pp. 619-627 ◽

Author(s):

Ann V Schwartz ◽

Karen C Johnson ◽

Steven E Kahn ◽

John A Shepherd ◽

Michael C Nevitt ◽

...

Keyword(s):

Bone Mineral Density ◽

Type 2 Diabetes ◽

Weight Loss ◽

Randomized Trial ◽

Weight Loss Intervention ◽

Mineral Density ◽

Intentional Weight Loss ◽

Download Full-text

Decision letter for "A greater proportion of participants with type 2 diabetes achieve treatment targets with IDegLira (insulin degludec/liraglutide) versus insulin glargine U100 at 26 weeks: DUAL VIII a randomized trial designed to resemble clinical practice"

10.1111/dom.13957/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Clinical Practice ◽

Insulin Glargine ◽

Randomized Trial ◽

Insulin Degludec ◽

Treatment Targets

Download Full-text

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13856 ◽

2019 ◽

Vol 21 (12) ◽

pp. 2674-2683 ◽

Author(s):

Kohei Kaku ◽

Eiichi Araki ◽

Yukio Tanizawa ◽

Bue Ross Agner ◽

Tomoyuki Nishida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Insulin Degludec ◽

Phase 3 ◽

Superior Efficacy

Download Full-text